Diabetes News and Research

Latest Diabetes News and Research

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

New diagnostic tool could help detect heart attacks

A diagnostic tool developed by Rice University scientists to detect heart attacks using a person's saliva is being tested at the Michael E. DeBakey VA Medical Center in collaboration with Baylor College of Medicine in Houston.

4 May 2010

Kidneys of healthy adults show signs of chronic mild injury that increase with age: Mayo Clinic

Mayo Clinic researchers have found that the kidneys of healthy adults show signs of chronic mild injury that increase with age. This damage is present even though the adults showed no clinical signs of kidney disease. The findings are reported in the current issue of the, Annals of Internal Medicine.

4 May 2010

One-half of physicians do not recommend bariatric surgery for adolescents

Severely obese adolescents may desire or potentially benefit from bariatric surgery. However, half of primary care physicians say they would not recommend the procedure to a patient under the age of 18, according to research published in Obesity Surgery

4 May 2010

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Sepracor Inc., a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), today announced that the U.S. Food and Drug Administration (FDA, or Agency) has issued a Complete Response Letter to Sepracor's New Drug Application (NDA) for its antiepileptic drug candidate, STEDESA™, which is the company's proposed trade name for eslicarbazepine acetate.

4 May 2010

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2010.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

With summer right around the corner, more people will be spending time outdoors and UV protection will be top of mind. Unfortunately, most people think about the protection of their skin, when they should also be considering the safety of their eyes. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, only one-third of Americans said UV protection is the most important factor they consider when purchasing sunglasses.

3 May 2010

BioTime acquires ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of human stem cells and regenerative medicine, today announced that it has completed its acquisition of the Singapore company ES Cell International Pte Ltd.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.

3 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

New classification of depressive subtypes of depression proposed

Lichtenberg and Belmaker propose a new classification of depressive subtypes of depression in the current issue of Psychotherapy and Psychosomatics. They argue that a simple diagnosis is no longer sufficient to guide treatment.

3 May 2010

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

The Scripps Research Institute has been awarded a $1.3 million grant by the National Institutes of Health (NIH) to develop a series of tests at its Florida campus to help explore the potential of a protein that has emerged as a highly attractive target for the treatment of obesity and Type 2 diabetes.

3 May 2010

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

The rheumatoid arthritis treatment Humira will replace Lipitor as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff according to the World Preview 2016 report published today by EvaluatePharma, the premier provider of pharma and biotech analysis.

3 May 2010

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

Results of a new study found that the investigational triple combination therapy of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) demonstrated significantly greater mean reductions at week 12 in blood pressure (37.1/21.8 mm Hg versus 27.5 to 30.0/15.1-18.0 mm Hg LS Mean Reductions, P< 0.0001), as compared to corresponding dual combination therapy (dual components).

3 May 2010

EHR with controlled interventions can produce optimal BP control, reduce mortality

Electronic health records with controlled interventions can produce optimal blood pressure control and reduce mortality, according to data presented at the American Society of Hypertension Inc.'s 25th Annual Scientific Meeting and Exposition (ASH 2010).

3 May 2010

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Monitoring of cell viability and toxicity are critical to many areas of biological and biomedical research. This is true for understanding the molecular and biochemical pathways regulating cell viability, for developing therapeutic agents which modulate cell viability and for identifying potential cytotoxic side effects of potential therapeutic agents.

3 May 2010

Leptin hormone controls immune’s response to sepsis: Study

The hormone leptin, typically associated with body weight regulation, works within the central nervous system (CNS) to aid the immune system's defense against sepsis, researchers say.

3 May 2010

Taking vitamin D supplements during pregnancy safe for mother, baby: Study

Taking vitamin D supplements during pregnancy is not only safe for mother and baby, but also can prevent preterm labor/births and infections, according to results of a randomized controlled study to be presented at the Pediatric Academic Societies annual meeting in Vancouver, British Columbia, Canada.

3 May 2010

Diabetes News and Research

Latest Diabetes News and Research

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

New diagnostic tool could help detect heart attacks

Kidneys of healthy adults show signs of chronic mild injury that increase with age: Mayo Clinic

One-half of physicians do not recommend bariatric surgery for adolescents

Sepracor issued FDA Complete Response Letter for STEDESA NDA

Array BioPharma reports 18.4M revenue for third-quarter fiscal 2010

FDA issues advisory on prostate cancer drugs

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

BioTime acquires ES Cell International

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

New classification of depressive subtypes of depression proposed

Scripps Research Institute awarded grant to design assays for exploring potential target for obesity, Type 2 diabetes

Pfizer to maintain top spot in prescription sales through mergers and acquisitions

Triple combination therapy with OM, AML, HCTZ more effective at lowering blood pressure

EHR with controlled interventions can produce optimal BP control, reduce mortality

Roche's xCELLigence System helps study cell viability, cell death while testing cytotoxic compounds

Leptin hormone controls immune’s response to sepsis: Study

Taking vitamin D supplements during pregnancy safe for mother, baby: Study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Diabetes News and Research

Latest Diabetes News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in